ICON Public Limited Company (NASDAQ: ICLR) Overview and Financial Outlook

Font: Financial Modeling Prep  • Feb 23, 2026

• Jefferies analyst David Windley sets a price target of $135 for NASDAQ:ICLR, indicating a potential increase of approximately 35.41% from its current price.
• Levi & Korsinsky initiates an investigation into ICLR for potential violations of federal securities laws after a significant stock price decline.
• Despite recent challenges, ICLR reaffirmed its full-year 2025 guidance with expected revenue between $8.05 billion and $8.1 billion and adjusted EPS of $13.00 to $13.20.

ICON Public Limited Company (NASDAQ:ICLR) is a prominent player in the Contract Research Organization (CRO) sector, providing outsourced development services to the pharmaceutical, biotechnology, and medical device industries. The company is known for its comprehensive range of services that support clinical development, from early-phase research to post-approval studies. ICLR competes with other major CROs like IQVIA and LabCorp, striving to maintain its position in a competitive market.

On February 23, 2026, David Windley from Jefferies set a price target of $135 for ICLR, suggesting a potential increase of approximately 35.41% from its current price of $99.70. This optimistic outlook comes despite recent challenges faced by the company. Levi & Korsinsky has initiated an investigation into ICLR for potential violations of federal securities laws, following a significant single-day decline in the stock price. This decline erased billions in shareholder value, marking one of the largest percentage drops in the CRO sector in recent years.

Before this downturn, ICLR's stock had been trading within a range that reflected investor confidence in the company's financial outlook. The management had recently reaffirmed its full-year 2025 guidance, with expected revenue between $8.05 billion and $8.1 billion and adjusted earnings per share (EPS) guidance of $13.00 to $13.20. The sudden sell-off suggests that the market was caught off guard by potential risks, such as revenue overstatement or delays in earnings releases.

Currently, ICLR's stock is priced at $99.70, showing a slight increase of 1.29, or 1.31% in percentage terms. During the trading day, the stock fluctuated between a low of $96.83 and a high of $100.83. Over the past year, the stock has experienced significant volatility, reaching a high of $211 and a low of $66.57. With a market capitalization of approximately $7.61 billion, ICLR remains a significant player in the CRO sector, despite recent challenges. The trading volume for the day stands at 1,642,937 shares on the NASDAQ exchange, indicating active investor interest.